{"id":"entecavir-dispersible-tablets","safety":{"commonSideEffects":[{"rate":"10%","effect":"Headache"},{"rate":"8%","effect":"Nausea"},{"rate":"6%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL713","moleculeType":"Small molecule","molecularWeight":"277.28"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Entecavir is a nucleoside analogue that selectively inhibits the replication of hepatitis B virus (HBV) by competing with the natural nucleoside substrate for the viral DNA polymerase.","oneSentence":"Inhibits hepatitis B virus DNA polymerase","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:51:04.101Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B"}]},"trialDetails":[{"nctId":"NCT06990776","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects","status":"WITHDRAWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-07-09","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT06966232","phase":"PHASE3","title":"Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-15","conditions":"Gastrointestinal Cancers","enrollment":136},{"nctId":"NCT06150014","phase":"PHASE1, PHASE2","title":"A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-12-07","conditions":"Chronic Hepatitis b","enrollment":88},{"nctId":"NCT06566248","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-03-20","conditions":"Chronic Hepatitis B","enrollment":90},{"nctId":"NCT02777814","phase":"PHASE2","title":"Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-05-01","conditions":"Colorectal Neoplasms","enrollment":50},{"nctId":"NCT01943617","phase":"PHASE4","title":"Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2013-06","conditions":"Liver Cirrhosis","enrollment":606},{"nctId":"NCT01938820","phase":"PHASE4","title":"Optimized Treatment and Regression of HBV-induced Early Cirrhosis","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2013-06","conditions":"Liver Cirrhosis","enrollment":82},{"nctId":"NCT01938781","phase":"PHASE4","title":"Optimized Treatment and Regression of HBV-induced Liver Fibrosis","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2013-06","conditions":"Liver Fibrosis","enrollment":400},{"nctId":"NCT02777801","phase":"PHASE2","title":"Prophylactic or Preemptive Entecavir in Patients With Gastric Cancer Who Are Inactive Hepatitis B Carriers","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-06","conditions":"Stomach Neoplasms","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DRUG ERUPTION"},{"count":2,"reaction":"PRURITUS"},{"count":2,"reaction":"PURPURA"},{"count":2,"reaction":"URINE OUTPUT DECREASED"}],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Entecavir dispersible tablets","genericName":"Entecavir dispersible tablets","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits hepatitis B virus DNA polymerase Used for Chronic hepatitis B.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}